Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer Statistics 2004. CA Cancer J Clin. 2004, 54: 8-29.
Article
PubMed
Google Scholar
Ries LAG, Kosary CL, Hankey BF, Miller BA, Harras A, Edwards BK: SEER Cancer Statistics Review, 1973-1994. National Cancer Institute. NIH Pub No 97-2789. 1997
Google Scholar
Steiner MS, Gingrich JR: Gene Therapy for Prostate Cancer: Where are we now?. Journal of Urology. 2000, 164: 1121-1136. 10.1097/00005392-200010000-00002.
Article
CAS
PubMed
Google Scholar
MacFarlane M: TRAIL-induced signalling and apoptosis. Toxicology Letters. 2003, 139: 89-97. 10.1016/S0378-4274(02)00422-8.
Article
CAS
PubMed
Google Scholar
Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert A, DeForge L, Koumenis IL, Lewis D, Harris L, Bussiere J, Koeppen H, Shahrokh Z, Schwall RH: Safety and antitumor activity of recombinant soluble Apo2 ligand. Journal of Clinical Investigation. 1999, 104: 155-162.
Article
CAS
PubMed
PubMed Central
Google Scholar
Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC, Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo [see comments]. Nature Medicine. 1999, 5: 157-163. 10.1038/5517.
Article
CAS
PubMed
Google Scholar
Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J, Fox JA: Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther. 2001, 299: 31-38.
CAS
PubMed
Google Scholar
Krueger A, Baumann S, Krammer PH, Kirchhoff S: FLICE-Inhibitory Proteins: Regulators of Death Receptor-Mediated Apoptosis. Mol Cell Biol. 2001, 21: 8247-8254. 10.1128/MCB.21.24.8247-8254.2001.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bullani RR, Huard B, Viard-Leveugle I, Byers HR, Irmler M, Saurat JH, Tschopp J, French LE: Selective expression of FLIP in malignant melanocytic skin lesions. Journal of Investigative Dermatology. 2001, 117: 360-364. 10.1046/j.0022-202x.2001.01418.x.
Article
CAS
PubMed
Google Scholar
Ryu BK, Lee MG, Chi SG, Kim YW, Park JH: Increased expression of cFLIP(L) in colonic adenocarcinoma. Journal of Pathology. 2001, 194: 15-19. 10.1002/path.835.
Article
CAS
PubMed
Google Scholar
Okano H, Shiraki K, Inoue H, Kawakita T, Yamanaka T, Deguchi M, Sugimoto K, Sakai T, Ohmori S, Fujikawa K, Murata K, Nakano T: Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Laboratory Investigation. 2003, 83: 1033-1043. 10.1097/01.LAB.0000079328.76631.28.
Article
CAS
PubMed
Google Scholar
Tepper CG, Seldin MF: Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. blood. 1999, 94: 1727-1737.
CAS
PubMed
Google Scholar
Jonsson G, Paulie S, Grandien A: High level of cFLIP correlates with resistance to death receptor-induced apoptosis in bladder carcinoma cells. Anticancer Research. 2003, 23: 1213-1218.
PubMed
Google Scholar
Voelkel-Johnson C, King DL, Norris JS: Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Therapy. 2002, 9: 164-172. 10.1038/sj.cgt.7700420.
Article
CAS
PubMed
Google Scholar
Kelly MM HBHVJC: Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biology & Therapy. 2002, 1: 520-527.
Article
Google Scholar
Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand [see comments]. Nature Medicine. 2000, 6: 564-567. 10.1038/75045.
Article
CAS
PubMed
Google Scholar
Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow P, Hooley J, Sherwood S, Pai R, Leung S, Khan L, Gliniak B, Bussiere J, Smith CA, Strom SS, Kelley S, Fox JA, Thomas D, Ashkenazi A: Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nature Medicine. 2001, 7: 383-385. 10.1038/86397.
Article
CAS
PubMed
Google Scholar
Irmler M, Thome M, Hahne M, Schneider P, Hofmann B, Steiner V, Bodmer JL, Schroter M, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J: Inhibition of Death Receptor Signals By Cellular Flip. Nature. 1997, 388: 190-195. 10.1038/40657.
Article
CAS
PubMed
Google Scholar
Yeh WC, Itie A, Elia AJ, Ng M, Shu HB, Wakeham A, Mirtsos C, Suzuki N, Bonnard M, Goeddel DV, Mak TW: Requirement for casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity. 2000, 12: 633-642. 10.1016/S1074-7613(00)80214-9.
Article
CAS
PubMed
Google Scholar
Arah IN, Song K, Seth P, Cowan KH, Sinha BK: Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells. Anticancer Research. 1998, 18: 1845-1849.
CAS
PubMed
Google Scholar
Fulda S, Meyer E, Debatin KM: Metabolic inhibitors sensitize for CD95 (APO-1/Fas)-induced apoptosis by down-regulating Fas-associated death domain-like interleukin 1-converting enzyme inhibitory protein expression. Cancer Research. 2000, 60: 3947-3956.
CAS
PubMed
Google Scholar
Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, Krammer PH, Peter ME, Wyche JH, Pantazis P: Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIPshort. Cancer Research. 2001, 61: 7148-7154.
CAS
PubMed
Google Scholar
Kinoshita H, Yoshikawa H, Shiiki K, Hamada Y, Nakajima Y, Tasaka K: Cisplatin (CDDP) sensitizes human osteosarcoma cell to Fas/CD95-mediated apoptosis by down-regulating FLIP-L expression. International Journal of Cancer. 2000, 88: 986-991. 10.1002/1097-0215(20001215)88:6<986::AID-IJC23>3.0.CO;2-B.
Article
CAS
PubMed
Google Scholar
Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ: The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood. 2003, 102: 303-310. 10.1182/blood-2002-09-2975.
Article
CAS
PubMed
Google Scholar
Siegmund D, Hadwiger P, Pfizenmaier K, Vornlocher HP, Wajant H: Selective inhibition of FLICE-like inhibitory protein (FLIP) expression with small interfering RNA oligonucleotides (siRNAs) is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Molecular Medicine. 2002, 8: 725-732.
CAS
PubMed
PubMed Central
Google Scholar
Hyer ML, Sudarshan S, Kim Y, Reed JC, Dong JY, Schwartz DA, Norris JS: Down-regulation of c-FLIP sensitizes DU145 prostate cancer cells to Fas-mediated apoptosis. Cancer Biol Ther. 2002, 1: 401-6.
Article
CAS
PubMed
Google Scholar
Shankar S, Singh TR, Srivastava RK: Ionizing Radiation Enhances the Therapeutic Potential of TRAIL in Prostate Cancer in vitro and in vivo: Intracellular Mechanisms. The Prostate. 2004, 61: 35-49. 10.1002/pros.20069.
Article
CAS
PubMed
Google Scholar
Gliniak B, Le T: Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Research. 1999, 59: 6153-6158.
CAS
PubMed
Google Scholar
Nagane M, Pan G, Weddle JJ, Dixit VM, Cavenee WK, Huang HJ: Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. Cancer Research. 2000, 60: 847-853.
CAS
PubMed
Google Scholar
Liu WH, Bodle E, Chen JY, Gao MX, Rosen GD, Broaddus VC: Tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy cooperate to induce apoptosis in mesothelioma cell lines. Am J Respir Cell Mol Biol. 2001, 25: 111-118.
Article
CAS
PubMed
Google Scholar
Keane MM, Ettenberg SA, Nau MM, Russell EK, Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Research. 1999, 59: 734-741.
CAS
PubMed
Google Scholar